Gilead Sciences, Inc. (GILD)
NASDAQ • Healthcare
October 14, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 15 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Gilead Sciences topped revenue expectations on preliminary second fiscal quarter of 2026 results reported Aug. 4, as revenue rose 10.2% to about $7.8 billion from $7.08 billion a year ago and beat the about $7.4 billion consensus by 5.5%. Total product sales, the largest segment, rose 5.0% to about $7.0 billion, while the U.S. remained the biggest geographic concentration at about $4.9 billion, up 5.5%. Gross profit came in at roughly $6.2 billion and gross margin held near 80%, with operating cash flow of $3.57 billion and $1.04 billion paid in dividends. Consensus for the next period calls for EPS of $2.16 on revenue of $7.76 billion.
Next report — what to expect
Gilead Sciences, Inc. (GILD) is set to report earnings on October 29, 2026. Wall Street is looking for consensus EPS of $2.12 on consensus revenue of $7.77 billion. For trailing context, revenue rose +10.2% year over year last quarter. Gilead has beaten EPS in 8 of 8 most recent quarters.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. discovers, develops, and commercializes medicines for critical health needs and trades on the NASDAQ as GILD. The biopharmaceutical company sits in healthcare, with FY2025 revenue of $29.4 billion, and its portfolio spans antiviral therapies, oncology and cell therapy products, and specialty cardiovascular treatments.
Today's Snapshot
GILD closed 3.8% higher, within reach of the top of its 52-week range. Gilead Sciences partnered with Vir Biotechnology, an immunology drugmaker, to develop treatments for solid tumors.
Trading Volume
Above 10d avg 5.2M
5.7M
vs S&P 500 Today
Strong Outperformance
+4.94%
Updated: October 14, 2026 at 20:19 UTC
GILD Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$137.49 - $149.26Buy
- RSI (14)61.04Neutral
- Stochastic %K (14, 3, 3)72.26Neutral
- MACD Level (12, 26)1.02Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.